Dx Strategy: Strategic Planning to Enable China Joining Global Clinical Trials with Simultaneous Filing Intent

• Showcasing study kick off efforts and timeline in China including HGR related information
• Reviewing Dx development strategy to align with global and to support CN trial
• Discussing high level drug filing plan with Dx being a component

Speakers:

Sophie Cui

Director - Biomarker, IVD

Gilead Sciences